Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review

Neurology

Volumn 83, Issue 13, 2014, Pages 1170-1177

  Izcovich, Ariel ^a   Malla, Carlos González ^a   Manzotti, Matias ^a   Catalano, Hugo Norberto ^a   Guyatt, Gordon ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MIDODRINE; PLACEBO;

ARTICLE; ATTRIBUTABLE RISK; AUTONOMIC DYSFUNCTION; CHILL; CONFIDENCE INTERVAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FAINTNESS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT REFLEX SYNCOPE; REFLEX; SCALP PRURITUS; SYSTEMATIC REVIEW; URINARY HESITANCY; URINARY URGENCY; URINE RETENTION; DRUG EFFECTS; HYPOTENSION, ORTHOSTATIC; PHYSIOLOGY; SECONDARY PREVENTION; SYNCOPE;

HUMANS; HYPOTENSION, ORTHOSTATIC; MIDODRINE; QUALITY OF LIFE; REFLEX; SECONDARY PREVENTION; SYNCOPE;

EID: 84921824157     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000815     Document Type: Article

References (40)

1. Colman N, Nahm K, Ganzeboom KS, et al. Epidemiology of reflex syncope. Clin Auton Res 2004;14(suppl 1):9-17.
2. Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United States. Am J Med 2007;120:975-980.
3. Kaufmann H. Neurally mediated syncope and syncope due to autonomic failure: differences and similarities. J Clin Neurophysiol 1997;14:183-196.
4. Schroeder C, Tank J, Heusser K, Diedrich A, Luft FC, Jordan J. Physiological phenomenology of neurally-mediated syncope with management implications. PLoS One 2011;6: e26489.
5. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation 2009; 119:139-146.
6. Fedorowski A, Burri P, Juul-Möller S, Melander O. A dedicated investigation unit improves management of syncopal attacks (Syncope Study of Unselected Population in Malmo-SYSTEMA I) 2010;12:1322-1328.
7. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006; 13:930-936.
8. Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS); Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009;30:2631-2671.
9. Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA 2012;21:1124-1127.
10. Romme JJ, Reitsma JB, Black CN, et al. Drugs and pacemakers for vasovagal, carotid sinus and situational syncope. Cochrane Database Syst Rev 2011;10:CD004194.
11. Liao Y, Li X, Zhang Y, et al. Alpha-adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data. Acta Paediatr 2009;98:1194-1200.
12. Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing 2012; 41:587-594.
13. Parsaik AK, Singh B, Altayar O, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med 2013;24:1496-1503.
14. Gehanno JF, Rollin L, Darmoni S. Is the coverage of Google Scholar enough to be used alone for systematic reviews. BMC Med Inform Decis Mak 2013;13:7.
15. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3: rating the quality of evidence. J Clin Epidemiol 2011;64:401-406.
16. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4: rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011;64:407-415.
17. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 6: rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283-1293.
18. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. GRADE guidelines: 7: rating the quality of evidence- inconsistency. J Clin Epidemiol 2011;64:1294-1302.
19. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8: rating the quality of evidence-indirectness. J Clin Epidemiol 2011;64:1303-1310.
20. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5: rating the quality of evidence-publication bias. J Clin Epidemiol 2011;64:1277-1282.
21. Lachner O, Lillie C, Rot A. The pharmacological properties of Midodrin and its clinical application in patients with hypotensive circulatory disturbance [in German]. Wien Klin Wochenschr 1974;86:344-348.
22. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48.
23. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 1995;99:604-610.
24. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051.
25. Ward CR, Gray JC, Gilroy JJ, et al. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998;79:45-49.
26. Wright RA, Kaufmann HC, Perera R, et al. A doubleblind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-124.
27. Perez-Lugones A, Schweikert R, Pavia S, et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol 2001;12:935-938.
28. A multi-center, double-blind, randomized, placebocontrolled, crossover study to assess the clinical benefit of midodrine hydrochloride in subjects with moderate to severe neurogenic orthostatic hypotension. Available at: www.ClinicalTrials.gov. Accessed March 2012.
29. Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr 2006;149:777-780.
30. Liu XY, Wang C, Wu LJ, et al. Efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope [in Chinese]. Zhonghua Yi Xue Za Zhi 2009;89: 1951-1954.
31. Romme JJ, van Dijk N, Go-Schön IK, et al. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace 2011;13:1639-1647.
32. A study for patients with neurogenic orthostatic hypotension. Available at: www.ClinicalTrials.gov. Accessed March 2012.
33. A phase IV study in subjects with neurogenic orthostatic hypotension. Available at: www.ClinicalTrials.gov. Accessed March 2012.
34. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The orthostatic hypotension questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012;22:79-90.
35. Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality Scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007;23:731-739.
36. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13: preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 2013;66:173-183.
37. Pringle E, Phillips C, Thijs L, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003;21:2251-2257.
38. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci 2011;310:123-128.
39. Romme JJ, Reitsma JB, Go-Schön IK, et al. Prospective evaluation of non-pharmacological treatment in vasovagal syncope. Europace 2010;12:567-573.
40. Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-1549.